Literature DB >> 8832020

Successful cord blood stem cell transplantation for congenital erythropoietic porphyria (Gunther's disease).

I Zix-Kieffer1, B Langer, D Eyer, G Acar, E Racadot, G Schlaeder, F Oberlin, P Lutz.   

Abstract

Congenital erythropoietic porphyria (Gunther's disease, GD) is a rare autosomal recessive disease. It results from the deficiency of uroporphyrinogen III synthase, the fourth enzyme on the metabolic pathway of heme synthesis. GD leads to severe scarring of the face and hands as a result of photosensitivity and fragility of the skin due to uroporphyrin I and coproporphyrin I accumulation. It also causes erythrocyte fragility leading to haemolytic anaemia. The other clinical features include hirsutism, red discolouration of teeth, finger-nails and urine and stunted growth. The outcome is poor, and the disfiguring nature of GD may partly explain the legend of the werewolf. No curative treatment was known until 1991, when the first case of BMT in GD was reported. The clinical and biological outcome after transplantation was encouraging, with an important regression of the symptoms of the disease, but the child died of CMV-infection 11 months after BMT. We report the second case of GD treated successfully by stem cell transplantation using umbilical cord blood from an HLA-identical brother in a 4-year-old girl suffering from severe GD. Our patient is very well 10 months after transplantation. We confirm that stem cell transplantation is curative for GD.

Entities:  

Mesh:

Year:  1996        PMID: 8832020

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

1.  Cord blood banking.

Authors: 
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

2.  Inducing iron deficiency improves erythropoiesis and photosensitivity in congenital erythropoietic porphyria.

Authors:  Daniel N Egan; Zhantao Yang; John Phillips; Janis L Abkowitz
Journal:  Blood       Date:  2015-05-13       Impact factor: 22.113

3.  Gene transfer of the uroporphyrinogen III synthase cDNA into haematopoietic progenitor cells in view of a future gene therapy in congenital erythropoietic porphyria.

Authors:  F Mazurier; F Moreau-Gaudry; S Salesse; C Barbot; C Ged; J Reiffers; H de Verneuil
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

4.  Congenital erythropoietic porphyria: characterization of murine models of the severe common (C73R/C73R) and later-onset genotypes.

Authors:  David F Bishop; Sonia Clavero; Narla Mohandas; Robert J Desnick
Journal:  Mol Med       Date:  2011-02-25       Impact factor: 6.354

Review 5.  Erythropoietic and hepatic porphyrias.

Authors:  U Gross; G F Hoffmann; M O Doss
Journal:  J Inherit Metab Dis       Date:  2000-11       Impact factor: 4.982

6.  Successful match-unrelated donor bone marrow transplantation for congenital erythropoietic porphyria (Günther disease).

Authors:  Sophie Dupuis-Girod; Véronique Akkari; Cécile Ged; Claire Galambrun; Kamila Kebaïli; Jean-Charles Deybach; Alain Claudy; Lucette Geburher; Noël Philippe; Hubert de Verneuil; Yves Bertrand
Journal:  Eur J Pediatr       Date:  2004-11-20       Impact factor: 3.183

7.  Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells.

Authors:  Elodie Robert-Richard; François Moreau-Gaudry; Magalie Lalanne; Isabelle Lamrissi-Garcia; Muriel Cario-André; Véronique Guyonnet-Dupérat; Laurence Taine; Cécile Ged; Hubert de Verneuil
Journal:  Am J Hum Genet       Date:  2008-01       Impact factor: 11.025

Review 8.  Congenital erythropoietic porphyria: Recent advances.

Authors:  Angelika L Erwin; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2018-12-27       Impact factor: 4.797

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.